Investigating Humanin as a Novel Biomarker for Acute Kidney Injury

Acute Kidney Injury (AKI) is a sudden and severe reduction in kidney function, often leading to serious complications and increased mortality. Early detection of AKI is crucial for timely intervention and improved patient outcomes, but current diagnostic markers often lack sufficient sensitivity or specificity. This study aims to determine if plasma Humanin, a mitochondrial-derived peptide, can serve as a novel and reliable predictive biomarker for AKI.

While this observational study is ongoing with an estimated completion in June 2024, the researchers hypothesize that plasma Humanin levels will be significantly altered in patients with AKI compared to healthy controls. If successful, they anticipate finding a substantial difference, potentially showing Humanin levels to be 2-fold higher in AKI patients. This elevation could correlate with disease severity, with a hypothetical 30% increase in Humanin predicting a 2.5-fold higher risk of progression to severe AKI. The primary expected finding is that elevated plasma Humanin concentrations will demonstrate a strong predictive power for AKI onset, potentially achieving an AUC of 0.85 in ROC analysis, indicating excellent diagnostic accuracy. Furthermore, a hypothetical 15% reduction in Humanin levels during recovery could indicate a positive response to treatment, suggesting its potential as a monitoring tool.